Home > Insider Trading > Filing (0001399529-21-000052)

Filing Details

Accession Number:: 0001399529-21-000052
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-02 19:00:31
Reporting Period:: 2021-03-01

Accepted Time:: 2021-03-02 19:00:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598479	D Bob Brown	C/O Dicerna Pharmaceuticals, Inc. 75 Hayden Avenue Lexington MA 02421	Chief Scientific Ofr., Evp R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-01	8,312	$9.09	29,829	No	4	M	Direct
Common Stock	Disposition	2021-03-01	7,529	$28.90	22,300	No	4	S	Direct
Common Stock	Disposition	2021-03-01	783	$29.49	21,517	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-03-01	8,312	$0.00	8,312	$9.09

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
91,746		2026-01-08	No	4	M	Direct

Footnotes

The Reporting Person sold an aggregate of 8,312 shares of Common Stock on March 1, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.85% of 976,825 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.39 to $29.38, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.46 to $29.53, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
As of the transaction date, the option was fully vested. The option vested in 48 monthly installments over the four-year period with a vesting start date of January 8, 2016, subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.